Related Experiment Video

Updated: Jun 4, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Hepatitis B and hepatitis C virus and chronic kidney disease

F Fabrizi1, P Martin, P Messa

  • 1Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Milano, Italy. fabrizi@policlinico.mi.it

Acta Gastro-Enterologica Belgica
|February 9, 2011
PubMed

Insights

Hepatitis B (HBV) and Hepatitis C (HCV) infections significantly increase mortality in chronic kidney disease (CKD) patients. Careful donor selection and targeted therapies are crucial for managing these viral infections in CKD and transplant recipients.

Area of Science:

  • Nephrology
  • Hepatology
  • Transplantation Immunology

Background:

  • Hepatitis B virus (HBV) and hepatitis C virus (HCV) are leading causes of liver disease in chronic kidney disease (CKD) patients.
  • These viral infections are associated with increased mortality and complications in CKD patients, including post-transplant outcomes.

Purpose of the Study:

  • To review the impact of HBV and HCV on CKD patient survival and post-renal transplant outcomes.
  • To discuss current therapeutic strategies and donor selection criteria for HBV and HCV in CKD and transplant populations.

Main Methods:

  • Literature review of studies investigating HBV and HCV in CKD patients.
  • Analysis of registry data on renal transplantation outcomes in HCV-infected recipients.
  • Summary of current treatment guidelines for HBV and HCV in dialysis and post-transplant settings.

Main Results:

  • HBV and HCV infections contribute to excess mortality in CKD patients, partly due to liver disease complications.
  • HCV infection negatively impacts renal transplant survival, associated with both hepatic and extrahepatic complications.
  • Transmission of HCV via donor kidneys is confirmed, increasing recipient mortality risk; restricting infected grafts to viremic recipients is advised.
  • Limited data exists for newer HBV therapies in CKD; lamivudine is the most studied.
  • Conventional interferon monotherapy is the standard for HCV in dialysis patients, with limited use post-transplant.

Conclusions:

  • HBV and HCV pose significant risks to CKD patients and renal transplant recipients.
  • Strategic donor selection and appropriate, guideline-adherent therapies are essential for managing these viral infections.
  • Further research is needed on novel HBV therapies in the CKD population.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...